FRLN

Syncona’s portfolio company, Freeline, releases positive data on gene therapy for Gaucher disease

Syncona Ltd notes further safety and enzyme activity data from its portfolio company, Freeline Therapeutics, on its gene therapy candidate for Gaucher disease...
Search

Funds

News

Syncona’s portfolio company, Freeline, releases positive data on gene therapy for Gaucher disease

Syncona Ltd notes further safety and enzyme activity data from its portfolio company, Freeline Therapeutics, on its gene therapy candidate for Gaucher disease...
Search

Funds

FRLN

FTSE 100

Funds